LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
|Articles|October 1, 2014
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Author(s)Emmanuel S. Antonarakis, MBBCh
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
Advertisement
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
Clinical Pearls
- The study showed that about 39% (12 of 31) of patients in the enzalutamide arm had AR-V7 detected in their circulating tumor cells.
- Every patient taking enzalutamide that had AR-V7 did not obtain a PSA response to enzalutamide.
- In the abiraterone arm, 19% (6 of 31) were found to have AR-V7.
- Similarly, all of these patients demonstrated resistance to abiraterone. ​
<<<
Advertisement
Related to this article
Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.
The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
Five ESMO 2026 abstracts report responses with 4 antibody-drug conjugates in ovarian cancer and a subcutaneous HER2-directed ADC plus PD-L1 inhibitor in cervical cancer.
Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.
ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab and pumitamig plus docetaxel showed activity in PD-L1–high and post-chemoimmunotherapy disease.
Advertisement
Advertisement
Trending on Targeted Onc
1
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
2
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5